Therapeutic Drug Monitoring

Breakthrough technology to enhance monoclonal antibody-based treatment

Labelled Bevacizumab 13C15N

Application

Absolute quantification of Avastin® or its biosimilars

Specific labelling

Arginine: 13C6,15N4, >99%

Lysine: 13C6,15N2, >99%

10 µg     ->    650 €      Quantity  

You must sign in or create an account to order this product

Description
Datasheet
Price

Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons.